Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft

Abroad (travel likely)RecruitingPHASE4

Conditions

Epstein-Barr Virus Infections

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    Contact: Study coordinator (Sophie Caillard, MD)